NBD-09027
NBD-09027 is a HIV-1 gp120 inhibitor. NBD-09027 blocks the gp120-CD4 interaction by binding to the Phe43 cavity of gp120, thereby inhibiting HIV-1-mediated cell fusion and the infectivity of multiple viral subtypes. NBD-09027 can be used in studies of human immunodeficiency virus type 1 infection.
For research use only. We do not sell to patients.
- CAS No.: 1376434-43-3
- Formula: C19H23ClN4O3S
- Molecular Weight:422.93
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
HIV |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H9 | IC50 |
2.3 μM
|
Inhibition of cell-cell fusion between HIV-1(IIIB)-infected H9 human T-cell leukemia cells and MT-2 human T-cell leukemia cells assessed by counting fused and unfused calcein-labeled cells after 3 h incubation by inverted fluorescence microscope.
Inhibition of cell-cell fusion between HIV-1(IIIB)-infected H9 human T-cell leukemia cells and MT-2 human T-cell leukemia cells assessed by counting fused and unfused calcein-labeled cells after 3 h incubation by inverted fluorescence microscope.
|
25001301 |
| TZM | IC50 |
0.7 μM
|
Inhibition of infection by clade C ZM135M.PL10a HIV-1 Env-pseudotyped reference virus in TZM-bl cells assessed by luciferase activity after 3 days incubation following 30 min preincubation of virus with reagent.
Inhibition of infection by clade C ZM135M.PL10a HIV-1 Env-pseudotyped reference virus in TZM-bl cells assessed by luciferase activity after 3 days incubation following 30 min preincubation of virus with reagent.
|
25001301 |
| TZM | IC50 |
> 21 μM
|
Inhibition of infection by clade C ZM197M.PB7 and ZM214M.PL15 HIV-1 Env-pseudotyped reference viruses in TZM-bl cells assessed by luciferase activity after 3 days incubation following 30 min preincubation of virus with reagent.
Inhibition of infection by clade C ZM197M.PB7 and ZM214M.PL15 HIV-1 Env-pseudotyped reference viruses in TZM-bl cells assessed by luciferase activity after 3 days incubation following 30 min preincubation of virus with reagent.
|
25001301 |
| TZM | CC50 |
> 32 μM
|
Cytotoxicity against TZM-bl cells.
Cytotoxicity against TZM-bl cells.
|
25001301 |
| MT2 | IC50 |
4 μM
|
Inhibition of laboratory-adapted HIV-1 isolates in human MT-2 cells assessed via p24 antigen ELISA after 4 days of incubation during viral infection.
Inhibition of laboratory-adapted HIV-1 isolates in human MT-2 cells assessed via p24 antigen ELISA after 4 days of incubation during viral infection.
|
25001301 |
| MT2 | IC50 |
35.8 μM
|
Inhibition of laboratory-adapted HIV-1 isolates in human MT-2 cells assessed via p24 antigen ELISA after 4 days of incubation during viral infection.
Inhibition of laboratory-adapted HIV-1 isolates in human MT-2 cells assessed via p24 antigen ELISA after 4 days of incubation during viral infection.
|
25001301 |
In Vitro
NBD-09027 (3 h) inhibits HIV-1-mediated cell-cell fusion between HIV-1IIIB-infected H9 cells and MT-2 cells, with an IC50 of 2.3 μM[1].
NBD-09027 (1 h) blocks the binding of CD4 to recombinant HIV-1IIIB gp120, with an IC50 of 6.2 μM[1].
NBD-09027 inhibits the infection of U87-CD4-CCR5 cells by R5-tropic NL4-3-ADA-Luc pseudovirus (IC50 = 9.1 μM) and the infection of U87-CD4-CXCR4 cells by X4-tropic NL4-3-HXB2-Luc pseudovirus (IC50 = 8.6 μM)[1].
NBD-09027 potently and selectively inhibits the infection of TZM-bl cells by multiple HIV-1 Env pseudotyped reference viruses of subtypes A, A/D, A2/D, A/E, A/G, B, C, and D, with IC50 values ranging from 0.7 μM to > 21 μM and a CC50 value of > 32 μM[1].
NBD-09027 (30-55 μM; for up to 9 weeks) selects drug-resistant viruses carrying the NN301-302KI, K432R, and V782L mutations during serial passage of NL4-3 HIV-1 in Jurkat cells[1].
NBD-09027 (4-7 days) inhibits the laboratory-adapted HIV-1 isolate in MT-2 cells with an IC50 range of 4-35.8 μM, but exhibits only weak or no activity against primary HIV-1 isolates of subtype C and group O in PBMCs[2].
NBD-09027 (4 h) exhibits weak inhibitory activity against the cell-to-cell transmission of CXCR4-tropic HIV-1 in GHOST (3) X4/R5 cells, with an IC50 of approximately 60 μM, and shows no inhibitory activity against the cell-to-cell transmission of CCR5-tropic HIV-1[2].
NBD-09027 (10-50 μM) dose-dependently inhibits the infectivity of CD4-dependent HIV-1 NL4-3-ADA-Luc in CD4-positive Cf2Th-CD4-CCR5 cells, with more potent inhibitory effects at higher concentrations up to 50 μM; meanwhile, it dose-dependently enhances the infectivity of CD4-independent HIV-1 NL4-3-ADA-N197S-Luc in CD4-negative Cf2Th-CCR5 cells[1].
NBD-09027 (10-50 μM) inhibits the infectivity of ENV-pseudotyped HIV-1 strains NIH #11313, NIH #11906, NIH #11601, and NIH #11890 in a dose-dependent manner, and its inhibitory effect increases when the concentration is elevated to 50 μM[1].
NBD-09027 (compound 6) exhibits consistently enhanced anti-HIV-1 activity against the vast majority of HIV-1 subtypes represented by a panel of 53 reference Env pseudoviruses[1].
NBD-09027 significantly reduces the CD4 agonist activity. Drug resistance selection confirms that it binds to the CD4 binding site on HIV-1 gp120, and mutations are detected at concentrations of 44 μM and 55 μM [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1376434-43-3
-
Molecular Weight 422.93
-
Formula C19H23ClN4O3S
-
SMILES
O=C(C(NC(C1NCCCC1)C2=NC(C)=C(CO)S2)=O)NC3=CC=C(C=C3)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Curreli F, et al. Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study. Antimicrob Agents Chemother. 2014 Sep;58(9):5478-91. [Content Brief]
[3]. Curreli F, et al. Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity. Journal of medicinal chemistry. 2015 Sep 10;58(17):6909-6927. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NBD-09027 Related Classifications
HY-116085 Related Classifications
Powered by Bioz